Managing Early Parkinson’s Disease |
Cindy Zadikoff, MD
Module 1: Disease Modifying Strategies and Alternative Therapies
Module 2: Treatment of Early Parkinson's Disease: Patient Selection and Medication Overview
Module 3: Considerations & Challenges When Initiating Medical Management For Parkinson's Disease & Translating Into Practice: Case Studies
Introduction
In the following audio webcast, Dr. Cindy Zadikoff, Northwestern University Feinberg School of Medicine will present the considerations and challenges in managing early Parkinson's disease, while providing a comprehensive overview including disease modifying strategies, alternative therapies, appropriate patient selection and therapeutic options.
Intended Audience
This continuing medical education program is intended for primary care physicians and other healthcare professionals who manage patients with Parkinson's disease.
Educational Objectives
Following the completion of this audio webcast program, the physician should be able to:
- Assess the current understanding of disease modifying strategies and alternative therapies for Parkinson's disease.
- Describe appropriate patient selection and treatment options for early Parkinson's disease.
- Evaluate the considerations and challenges when initiating treatment for Parkinson's disease.
Information on CME credit
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Medical Association designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Nonphysicians may receive a certificate of participation for completing this activity.
Instructions for CME credit
This online enduring material is presented as an audio webcast with attendant slide presentation. To receive credit, please view all of the presentations of these CME activity and evaluate the content presented. Complete both the pre- and post-test and activity evaluation.
The estimated time to complete this activity, including pre-test, review of the materials, and self-assessment and evaluation is 1.0 hour.
Advisory Board
William J. Weiner, MD, Chair
Professor of Neurology
Chair, Department of Neurology
Director, Maryland Parkinson's Disease and Movement Disorder Center
University of Maryland School of Medicine
Baltimore, MD
Shobha S. Rao, MD
Assistant Professor
Family and Community Medicine
Departments of Geriatric and Family Medicine
University of Texas Southwestern Medical School
Dallas, TX
Kathleen M. Shannon, MD
Associate Professor, Neurological Sciences
Department of Neurology
Rush Movements Disorders Group
Rush-Presbyterian-St. Luke's Medical Center
Rush Medical College
Chicago, IL
Oksana Suchowersky, MD, FRCPC, FCCMG
Professor and Head
Department of Medical Genetics
Director, Movement Disorders Program
University of Calgary
Calgary, AB, Canada
Editorial Board
R. Mark Evans, PhD
Director, Healthcare Education Products and Standards
American Medical Association
Chicago, IL
Kristi Eidsvoog, PhD
Content Manager
MedEd Architects, LLC
Chicago, IL
Patti Fitzgerald
Manager, Product Development, Healthcare Education Products and Standards
American Medical Association
Chicago, IL
Faculty:
Cindy Zadikoff, MD
Assistant Professor
Department of Neurology
Northwestern University Feinberg School of Medicine
Parkinson's Disease and Movement Disorder Center
Chicago, IL
Disclosure Policy
In order to assure the highest quality of CME programming, and to comply with the ACCME Standards for Commercial Support, the AMA requires that all faculty and planning committee members disclose relevant financial relationships with any commercial or proprietary entity producing health care goods or services relevant to the content being presented. We therefore obtain a completed disclosure and attestation form to inform the participant of any pertinent relationships disclosed, provided here.
These materials have been peer-reviewed by the members of the CME Advisory Board and the AMA Editorial Board to ensure the continued scientific accuracy and medical relevance of information presented and its independence from commercial bias. The AMA has control over all final content.
Dr. Rao: Nothing relevant to disclose
Dr. Shannon: Research Support, Kyowa, Schwarz, Teva, Schering/Titan; Consultant, Valeant, Prestwick
Dr. Suchowersky: Speaker's Bureau, Teva, Novartis; Advisory Board, Teva, Novartis
Dr. Weiner: Advisory Board, Novartis; Research Support, Boehringer-Ingelheim, Teva; Speaker's Bureau, Teva
Dr. Zadikoff: Nothing relevant to disclose
Editorial Staff
Dr. Evans: Nothing relevant to disclose
Dr. Eidsvoog: Nothing relevant to disclose
Ms. Fitzgerald: Nothing relevant to disclose
Acknowledgement of Support
This CME offering is supported through an independent education grant from Teva Neuroscience and produced in accordance with the AMA Standards for Industry-Supported Multimedia Continuing Medical Education and Other Communications.
Term of approval
December, 2007 through December, 2008


